HRTX icon

Heron Therapeutics

1.58 USD
-0.02
1.25%
At close Dec 24, 4:00 PM EST
After hours
1.63
+0.05
3.16%
1 day
-1.25%
5 days
-4.82%
1 month
38.60%
3 months
-19.39%
6 months
-50.31%
Year to date
-16.40%
1 year
-10.73%
5 years
-93.75%
10 years
-83.79%
 

About: Heron Therapeutics Inc is a commercial-stage biotechnology company. It is focused on improving the lives of patients by developing treatments that address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.

Employees: 126

0
Funds holding %
of 6,809 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

74% more repeat investments, than reductions

Existing positions increased: 66 | Existing positions reduced: 38

39% more call options, than puts

Call options by funds: $297K | Put options by funds: $214K

6.23% less ownership

Funds ownership: 86.54% [Q2] → 80.32% (-6.23%) [Q3]

9% less funds holding

Funds holding: 189 [Q2] → 172 (-17) [Q3]

25% less funds holding in top 10

Funds holding in top 10: 4 [Q2] → 3 (-1) [Q3]

44% less first-time investments, than exits

New positions opened: 22 | Existing positions closed: 39

47% less capital invested

Capital invested by funds: $456M [Q2] → $242M (-$214M) [Q3]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target
$4
153%
upside
Avg. target
$4
153%
upside
High target
$4
153%
upside

1 analyst rating

positive
100%
neutral
0%
negative
0%
Needham
Serge Belanger
37% 1-year accuracy
46 / 126 met price target
153%upside
$4
Buy
Reiterated
4 Dec 2024

Financial journalist opinion

Based on 3 articles about HRTX published over the past 30 days

Neutral
PRNewsWire
1 day ago
Heron Therapeutics Announces Corporate Headquarters Relocation to Cary, North Carolina
SAN DIEGO , Dec. 23, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, announced today the relocation of the Company's headquarters from San Diego, California to Cary, North Carolina, effective January 1, 2025. A majority of Heron's Management Team and corporate employees work from the Cary office, which is near the Research Triangle Park ("RTP"), one of the most prominent high-tech research and development parks in the United States.
Heron Therapeutics Announces Corporate Headquarters Relocation to Cary, North Carolina
Positive
Seeking Alpha
2 weeks ago
Relief For Heron Therapeutics After The Court Win On Cinvanti
Heron Therapeutics won a court case securing Cinvanti's patents until 2035, and removing a significant legal overhang on its largest revenue contributor. The court win allows the company to focus on growing the business. Heron missed Q3 revenue estimates, but the company expects a recovery in Cinvanti sales in Q4 due to new account wins, and it shared encouraging trends of Zynrelef and Aponvie.
Relief For Heron Therapeutics After The Court Win On Cinvanti
Neutral
PRNewsWire
3 weeks ago
U.S. District Court Upholds Validity of CINVANTI® Patents
— Court Rules in Favor of Heron in Patent Lawsuit Against Fresenius Kabi USA, LLC — SAN DIEGO , Dec. 3, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that the U.S. District Court for the District of Delaware ruled in Heron's favor in the Company's patent litigation against Fresenius Kabi USA, LLC with respect to CINVANTI® (aprepitant) injectable emulsion. The district court found that Heron's U.S. Patent Nos.
U.S. District Court Upholds Validity of CINVANTI® Patents
Neutral
Seeking Alpha
1 month ago
Heron Therapeutics, Inc. (HRTX) Q3 2024 Earnings Call Transcript
Heron Therapeutics, Inc. (NASDAQ:HRTX ) Q3 2024 Earnings Conference Call November 12, 2024 8:00 AM ET Company Participants Melissa Jarel - Executive Director Craig Collard - Chief Executive Officer Ira Duarte - Executive Vice President & Chief Financial Officer William Forbes - Executive Vice President & Chief Development Officer Conference Call Participants Carl Byrnes - Northland Capital Markets Serge Belanger - Needham Brandon Folkes - Rodman & Renshaw Operator Thank you for standing by and welcome to Heron Therapeutics Third Quarter 2024 Conference Call. At this time, all participants are in a listen-only mode.
Heron Therapeutics, Inc. (HRTX) Q3 2024 Earnings Call Transcript
Positive
Zacks Investment Research
1 month ago
Heron Therapeutics (HRTX) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
Although the revenue and EPS for Heron Therapeutics (HRTX) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Heron Therapeutics (HRTX) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
Neutral
Zacks Investment Research
1 month ago
Heron Therapeutics (HRTX) Reports Q3 Loss, Misses Revenue Estimates
Heron Therapeutics (HRTX) came out with a quarterly loss of $0.03 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.17 per share a year ago.
Heron Therapeutics (HRTX) Reports Q3 Loss, Misses Revenue Estimates
Neutral
PRNewsWire
1 month ago
Heron Therapeutics Announces Third Quarter 2024 Financial Results and Narrows Financial Guidance
Reported positive YTD 2024 Adjusted EBITDA of $1.4 million Company expects Q4 2024 Net Revenue in the range of $37 million - $43 million ZYNRELEF® (bupivacaine and meloxicam) extended-release solution Vial Access Needle ("VAN") approved in September and on track for Q4 2024 launch CMS Final Rule Non-Opioid Policy for Pain Relief includes ZYNRELEF as a qualifying product for separate payment in both the hospital outpatient department and ambulatory surgical center settings of care SAN DIEGO , Nov. 12, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced financial results for the three and nine months ended September 30, 2024, and highlighted recent corporate updates. "We are pleased to report that with our prudent financial management and continued revenue growth we were able to achieve positive Adjusted EBITDA for the quarter," said Craig Collard, Chief Executive Officer.
Heron Therapeutics Announces Third Quarter 2024 Financial Results and Narrows Financial Guidance
Neutral
Zacks Investment Research
1 month ago
Unveiling Heron Therapeutics (HRTX) Q3 Outlook: Wall Street Estimates for Key Metrics
Evaluate the expected performance of Heron Therapeutics (HRTX) for the quarter ended September 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Unveiling Heron Therapeutics (HRTX) Q3 Outlook: Wall Street Estimates for Key Metrics
Neutral
PRNewsWire
1 month ago
Heron Therapeutics Announces Appointment of Michael Kaseta to Board of Directors
SAN DIEGO , Nov. 4, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company, announced today the appointment of Michael Kaseta to its Board of Directors. Mr. Kaseta has an extensive background spanning corporate finance, business strategy, and the commercialization of biopharma products in large pharmaceutical companies and small biotech companies.
Heron Therapeutics Announces Appointment of Michael Kaseta to Board of Directors
Neutral
PRNewsWire
1 month ago
Heron Therapeutics to Report Third Quarter 2024 Financial Results On Tuesday, November 12, 2024
SAN DIEGO , Oct. 29, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that the Company will host a conference call and live webcast on Tuesday, November 12, 2024, at 8:00 a.m. ET to report third quarter 2024 financial results and discuss recent business highlights.
Heron Therapeutics to Report Third Quarter 2024 Financial Results On Tuesday, November 12, 2024
Charts implemented using Lightweight Charts™